Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
Coming Soon – August 2019
Glaucoma is a chronic and progressive disease of the optic nerve and is one of the leading causes of vision loss. Although the U.S. glaucoma therapy market is crowded and highly genericized, branded therapies have an important role. Recent-to-market therapies—Bausch + Lomb’s Vyzulta and Aerie Pharmaceuticals’ Rhopressa—and late-phase agents (e.g., Aerie’s Rocklatan, Allergan’s bimatoprost sustained release) offer some clinical benefits over current therapies. However, market access decisions for these therapies will play a key role in influencing ophthalmologists’ prescribing habits in glaucoma. Therefore, it is essential to assess how U.S. physicians and payers react to new brands entering a largely generic glaucoma market.
Geography: United States
Primary Research: Survey of ~100 U.S. ophthalmologists, survey of ~30 U.S. managed care organization (MCO) pharmacy and medical directors (PDs/MDs)
Key Drugs Covered: Travatan Z, Combigan, Lumigan, Simbrinza, Vyzulta, Rhopressa, Rocklatan, bimatoprost sustained release, latanoprost
Reimbursement and contracting
Access and prescribing
Opportunities and challenges for emerging therapies
U.S. Access & Reimbursement provides in-depth insight on the impact of payer policy on prescribing behavior so that clients can build their market access strategy and optimize their brand positioning. This analysis of primary market research with physician specialists and U.S. payers helps clients stay up-to-date on restriction policies, gauge payer and prescriber attitudes toward specific therapies, identify opportunities where brands can capture patient share through market access, and maximize opportunities for emerging therapies by learning how previous brands gained favorable reimbursement or why they stumbled.
Already a Client? Log in to access this report.
Himanshu is a Lead Analyst in the CNS/Ophthalmology team at Decision Resources Group, and has authored content for indications including age-related macular degeneration, diabetic retinopathy/diabetic macular edema, and unipolar depression. He comes with eight years of experience working on commercial assessment projects, including opportunity assessments, market intelligence, disease narratives, epi-based forecasts, patent research, and social media analysis, across multiple therapy areas. He holds a degree in Pharmacology from the National Institute of Pharmaceutical Education and Research (NIPER) in India and an Executive Post-Graduate Diploma in International Business from the Indian Institute of Foreign Trade.